
A meta-analysis of 14 studies (554 patients) found intravesical DMSO significantly reduced Interstitial Cystitis Symptom Index (−5.59), Problem Index (−5.14), and pain scores (−3.27), all with high statistical significance. Adverse events occurred in 37.6% of patients, but most were mild. These findings support intravesical DMSO as an effective and safe treatment option for interstitial cystitis/bladder pain syndrome.
Like
Save
Share